Verona Pharma PLC (VRNA)
15.87
+0.66
(+4.34%)
USD |
NASDAQ |
May 02, 15:06
Verona Pharma Enterprise Value: 1.006B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 1.006B |
| April 30, 2024 | 1.025B |
| April 29, 2024 | 1.034B |
| April 26, 2024 | 1.027B |
| April 25, 2024 | 1.014B |
| April 24, 2024 | 1.008B |
| April 23, 2024 | 1.037B |
| April 22, 2024 | 1.047B |
| April 19, 2024 | 1.047B |
| April 18, 2024 | 1.078B |
| April 17, 2024 | 1.102B |
| April 16, 2024 | 1.086B |
| April 15, 2024 | 1.053B |
| April 12, 2024 | 1.062B |
| April 11, 2024 | 1.083B |
| April 10, 2024 | 1.091B |
| April 09, 2024 | 1.108B |
| April 08, 2024 | 1.141B |
| April 05, 2024 | 1.152B |
| April 04, 2024 | 1.113B |
| April 03, 2024 | 1.088B |
| April 02, 2024 | 1.064B |
| April 01, 2024 | 1.074B |
| March 28, 2024 | 1.077B |
| March 27, 2024 | 1.110B |
| Date | Value |
|---|---|
| March 26, 2024 | 1.081B |
| March 25, 2024 | 1.046B |
| March 22, 2024 | 1.075B |
| March 21, 2024 | 1.066B |
| March 20, 2024 | 1.064B |
| March 19, 2024 | 1.013B |
| March 18, 2024 | 1.032B |
| March 15, 2024 | 1.041B |
| March 14, 2024 | 1.032B |
| March 13, 2024 | 1.125B |
| March 12, 2024 | 1.108B |
| March 11, 2024 | 1.062B |
| March 08, 2024 | 1.088B |
| March 07, 2024 | 1.129B |
| March 06, 2024 | 1.136B |
| March 05, 2024 | 1.147B |
| March 04, 2024 | 1.173B |
| March 01, 2024 | 1.247B |
| February 29, 2024 | 1.168B |
| February 28, 2024 | 1.171B |
| February 27, 2024 | 1.224B |
| February 26, 2024 | 1.201B |
| February 23, 2024 | 1.109B |
| February 22, 2024 | 1.128B |
| February 21, 2024 | 1.111B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.37M
Minimum
Mar 18 2020
1.762B
Maximum
Dec 31 2022
479.34M
Average
229.14M
Median
Enterprise Value Benchmarks
| NuCana PLC | -13.53M |
| TC BioPharm (Holdings) PLC | 1.592M |
| Biodexa Pharmaceuticals Plc | -1.818M |
| Adaptimmune Therapeutics PLC | 149.25M |
| Bicycle Therapeutics PLC | 420.98M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.13M |
| Total Expenses (Quarterly) | 18.06M |
| EPS Diluted (Quarterly) | -0.24 |
| Earnings Yield | -4.54% |
| Normalized Earnings Yield | -6.156 |